CKB inhibits epithelial-mesenchymal transition and prostate cancer progression by sequestering and inhibiting AKT activation.
Wang Z, Hulsurkar M, Zhuo L, Xu J, Yang H, Naderinezhad S, Wang L, Zhang G, Ai N, Li L, Chang JT, Zhang S, Fazli L, Creighton CJ, Bai F, Ittmann MM, Gleave ME, Li W.
Wang Z, et al. Among authors: naderinezhad s.
Neoplasia. 2021 Nov;23(11):1147-1165. doi: 10.1016/j.neo.2021.09.005. Epub 2021 Oct 24.
Neoplasia. 2021.
PMID: 34706306
Free PMC article.